U.S. pharma big copyright scrapped two experimental weight loss tablets very last year—a at the time-daily pill, lotiglipron, because of elevated liver enzymes and also a 2 times-daily capsule, danuglipron, because of potent Unintended effects—but CEO Albert Bourla has claimed the company is decided to “Participate in and get” from the bein